Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery

Published: Monday, June 27, 2011
Last Updated: Monday, June 27, 2011
Bookmark and Share
Partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.

Promega Corporation and ATCC (historically known as the American Type Culture Collection) have formed a partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.

In the partnership, ATCC will produce and authenticate cell banks and production lots of engineered and stock cell lines, which will be used as cellular reagents to create a new line of Promega cell assay systems for biologics. The initial cell assay system will facilitate biologics drug discovery.

Promega will launch an ADCC reporter bioassay in 2011 as the first product offering from this partnership. The ADCC (Antibody Dependent Cell-mediated Cytotoxicity) reporter bioassay will meet a particularly critical need for nearly all antibody-based biologics drug discovery programs worldwide.

These and other custom cell system assays will provide reduced variability to bioassays for biologics. The ADCC and other bioassay systems are currently in alpha and beta testing programs for qualification by leading manufacturers of biologics drugs.

ATCC is the recognized leader in biological materials management and processes for cell provisioning. "We are extremely pleased to work with Promega in bringing their assay innovations to drug discovery researchers", said Dr. Sherry Challberg, Sr. Director of Corporate Development for ATCC.

ATCC's President, Dr. Brian Pollok added, "We are excited to begin a venture of working with technology-based companies like Promega in the area of cellular assay product development."

Promega's Vice President of Life Sciences Products and Services, Thomas Livelli commented, "We believe this new offering will be extremely helpful to scientists and provide high value cell-based systems for discovery and development."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promega to Break Ground for New Processing and Manufacturing Facility
Facility will allow for efficiency improvements for processing, packaging, staging and shipping products.
Monday, July 07, 2014
Promega Expansion into Brazil Brings New Convenience and Support for Scientists
Now scientists in life science research, drug discovery and clinical diagnostics have direct access to technical service, fast delivery and the ability to request a quote online in Brazil.
Thursday, April 07, 2011
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!